iSpecimen Inc.
No enriched coverage for $ISPC in the last 7 days.
No SEC Form 4 filings for $ISPC in the last 30 days.
See all $ISPC insider activity →iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 9, 2026, iSpecimen Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of the close of business on August 12, 2026, the record date for the Special Meeting, there were 2,
iSpecimen Inc (NASDAQ:ISPC) shares rose 27.9% to $1.97 in pre-market trading after announcing a $4.5M acquisition of Foldlab AI assets. Novartis AG (NYSE:NVS) shares fell 12.7% to $139.56 following a failed clinical trial. Other stocks also moved significantly in pre-market trading.
iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Foldlab AI Ltd., a company organized under the laws of British Columbia (“Foldlab”
Recent ISPC coverage spans corporate actions, financial news and market movers.
The approvals clear regulatory hurdles and set the stage for future financing, but immediate price impact is limited.
The acquisition expands iSpecimen's AI portfolio, likely boosting revenue prospects.
The acquisition expands iSpecimen's AI portfolio but involves modest cash and stock consideration, with escrow restrictions that may limit immediate share liquidity.
Leadership transition may affect strategic direction and investor sentiment.
The fulfillment demonstrates operational capability and may boost client confidence, potentially supporting short‑term share demand.
AlphAI scores every news story that mentions ISPC with an AI model for sentiment and relevance, and aggregates insider trades from iSpecimen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 9, 2026, iSpecimen Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of the close of business on August 12, 2026, the record date for the Special Meeting, there were 2,
1 min readiSpecimen Inc (NASDAQ:ISPC) shares rose 27.9% to $1.97 in pre-market trading after announcing a $4.5M acquisition of Foldlab AI assets. Novartis AG (NYSE:NVS) shares fell 12.7% to $139.56 following a failed clinical trial. Other stocks also moved significantly in pre-market trading.
2 min readiSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Foldlab AI Ltd., a company organized under the laws of British Columbia (“Foldlab”
1 min readiSpecimen Inc. (ISPC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. Departure of Chief Executive Officer On August 26, 2026, Katharyn Field informed the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) of her decision t
1 min readiSpecimen (NASDAQ: ISPC) completed an international cancer research order involving hundreds of blood specimens, delivered within three weeks. The project showcased the company's ability to source and fulfill large-scale biospecimen requests quickly, leveraging its global network of healthcare and research partners.
1 min readiSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 12, 2026, iSpecimen Inc. (the “Company”) entered into a Consulting Agreement (the “Consulting Agreement”) with IR Agency LLC (the “Consultant”), pursuant to which the Consultant agreed to provide marketing and adver
2 min readiSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, iSpecimen Inc. (the “Company”) entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with WestPark Capital, Inc. (“WestPark”) to resolve all disputes between them, including the
2 min readiSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists
4 min readiSpecimen Inc. (NASDAQ:ISPC) announced it secured approximately $5.5 million in funding through a private placement of Series C Convertible Preferred Stock with accredited investors. The company plans to use the net proceeds for marketing, working capital, and general corporate purposes, with the offering expected to close around December 31, 2025. This funding comes as iSpecimen addresses potential cash burn concerns and recent Nasdaq non-compliance notice regarding its minimum bid price, alongside shareholder approval of a reverse stock split.
4 min readiSpecimen Inc. (NASDAQ: ISPC) announced a private placement aiming to raise approximately $5.5 million by issuing 6,875 shares of Series C Convertible Preferred Stock at $800 each. The net proceeds are intended for marketing, working capital, and general corporate purposes, with the closing expected around December 31, 2025. Following the announcement, iSpecimen's stock gained 39.96%, indicating a significant positive market reaction.
2 min read
